Feng Deng - 22 Jul 2021 Form 3 Insider Report for Cytek BioSciences, Inc. (CTKB)

Role
Director
Signature
/s/ Valerie Barnett, Attorney-in-Fact for Feng Deng
Issuer symbol
CTKB
Transactions as of
22 Jul 2021
Net transactions value
$0
Form type
3
Filing time
22 Jul 2021, 21:05:04 UTC
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CTKB Series A Preferred Stock 22 Jul 2021 Common Stock 147,933 See footnote F1, F2
holding CTKB Series C Preferred Stock 22 Jul 2021 Common Stock 4,168,777 See footnote F1, F2
holding CTKB Series D Preferred Stock 22 Jul 2021 Common Stock 443,800 See footnote F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date.
F2 Shares held directly by Northern Light Venture Capital V, Ltd. ("NLVC V"). Fund V serves as the nominee for each of Northern Light Venture Fund V, L.P., Northern Light Strategic Fund V, L.P. and Northern Light Partners Fund V, L.P (together, the "NLVC V Funds"). Northern Light Partners V, L.P., a Cayman Islands exempted limited liability partnership, is the general partner of the NLVC V Funds. NLVC V is the general partner of Northern Light Partners V, L.P. Feng Deng is the controlling shareholder of NLVC V and may be deemed to have voting and dispositive power with respect to the shares held by NLVC V.

Remarks:

Exhibit 24 - Power of Attorney